Loading clinical trials...
Loading clinical trials...
Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma
Conditions
Interventions
azacitidine
bortezomib
+1 more
Locations
1
United States
Ohio State University Medical Center
Columbus, Ohio, United States
Start Date
May 1, 2010
Primary Completion Date
May 1, 2012
Completion Date
December 1, 2012
Last Updated
December 3, 2013
NCT07388563
NCT06561048
NCT04195633
NCT04925609
NCT00336063
NCT03278782
Lead Sponsor
Pierluigi Porcu
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions